Blog - Latest News

Congenital Hyperinsulinism International

2017-06-22/in News /by Admino

AMIDEBIO CTO Dr. Michael Stowell will present a talk titled “Novel Pumpable Glucagons for Treating Hyperinsulinism” at the 2017 International Congenital Hyperinsulinism Conference July 15-16.

AMIDEBIO Granted Orphan Drug Designation by FDA for Novel Solution Stable Glucagon2020-04-22 - 17:35
AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Office of Orphan Products Development granted an orphan drug designation to AmideBio’s glucagon analog (ABG-023) for the treatment of congenital hyperinsulinism (CHI). ABG-023 is a solution stable, soluble glucagon analog designed to overcome the limitations of glucagon – […]
AMIDEBIO Awarded $1.56M SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism2019-09-30 - 07:33
AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The goal of this two-year grant is to enable an Investigational New Drug (IND) filing with the […]
David Brunel Takes Over Chairmanship at AmideBio2018-11-16 - 08:47
AmideBio LLC, a privately held biopharmaceutical company, announced today that David Brunel, a board member of AmideBio, has assumed the role of Chairman of the Board, replacing Misha Plam. Dr. Plam, a founder of AmideBio who retired recently as President and CEO, is now Chairman Emeritus. Read the full press release.